Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsBrian Luque - Head of Investor Relations ...

Empower Pharmacy markets itself as a well-meaning rival to Big Pharma - one that seeks to democratize medicine by making ...

It is now possible, for example, to connect regulatory and quality data and content, particularly product documentation ... 1 agonist semaglutide, ending sales of compounded forms.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

This comprehensive review explores MEDVi, a leading telehealth provider offering compounded GLP-1 weight loss solutions like Semaglutide and Tirzepatide in both injection and tablet form.

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 ...